Literature DB >> 12214577

Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-density [correction for destiny] lipoprotein.

Tomoki Okuda, Tsunao Oh-i.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12214577     DOI： 10.1007/s00228-002-0431-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  9 in total

Review 1.  Cyclosporine.

Authors:  B D Kahan
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

2.  High-dose cyclosporine therapy in recurrent nephrotic syndrome following renal transplantation.

Authors:  E Ingulli; A Tejani; K M Butt; D Rajpoot; R Gonzalez; A Pomrantz; R Ettenger
Journal:  Transplantation       Date:  1990-01       Impact factor: 4.939

3.  High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia.

Authors:  J Nemunaitis; H J Deeg; G C Yee
Journal:  Lancet       Date:  1986-09-27       Impact factor: 79.321

4.  Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%.

Authors:  O A Rayyes; A Wallmark; C H Florén
Journal:  Hepatology       Date:  1996-09       Impact factor: 17.425

5.  Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

Authors:  O al Rayyes; A Wallmark; C H Florén
Journal:  Hepatology       Date:  1997-04       Impact factor: 17.425

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Cyclosporine, low-density lipoprotein, and cholesterol.

Authors:  P C de Groen
Journal:  Mayo Clin Proc       Date:  1988-10       Impact factor: 7.616

8.  Cyclosporine A-induced side effects related to a low total serum cholesterol level: an indication for a free cyclosporine A assay?

Authors:  P C de Groen; R H Wiesner; R A Krom
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

Review 9.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714
  9 in total
  1 in total

1.  Decreased cyclosporine exposure during the remission of nephrotic syndrome.

Authors:  Mara Medeiros; José Pérez-Urizar; Natalia Mejía-Gaviria; Eduardo Ramírez-López; Gilberto Castañeda-Hernández; Ricardo Muñoz
Journal:  Pediatr Nephrol       Date:  2006-10-20       Impact factor: 3.714
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.